Ignite Creation Date:
2024-05-05 @ 4:45 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00305487
Status:
COMPLETED
Last Update Posted:
2016-11-30
First Post:
2006-03-21
Brief Title:
Safety and Efficacy of Ciclesonide in Pediatric Patients 6 to 11 Years of Age With Seasonal Allergic Rhinitis BY9010M1-417
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Parallel-Group Clinical Trial Designed to Assess the Safety and Efficacy of Ciclesonide 200mcg and 100mcg Once Daily Applied as a Nasal Spray for Two Weeks in the Treatment of Seasonal Allergic Rhinitis SAR in Patients 6 to 11 Years of Age
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to determine the efficacy and safety of ciclesonide nasal spray in children with seasonal allergic rhinitis Ciclesonide will be administered intranasally at two dose levels once daily The study consists of a baseline period 1 to 3 weeks and a treatment period 2 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None